These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21812019)

  • 1. Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.
    Aue G; Nelson Lozier J; Tian X; Cullinane AM; Soto S; Samsel L; McCoy P; Wiestner A
    Am J Hematol; 2011 Oct; 86(10):835-40. PubMed ID: 21812019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
    Aue G; Njuguna N; Tian X; Soto S; Hughes T; Vire B; Keyvanfar K; Gibellini F; Valdez J; Boss C; Samsel L; McCoy JP; Wilson WH; Pittaluga S; Wiestner A
    Haematologica; 2009 Sep; 94(9):1266-73. PubMed ID: 19734418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
    Andritsos LA; Johnson AJ; Lozanski G; Blum W; Kefauver C; Awan F; Smith LL; Lapalombella R; May SE; Raymond CA; Wang DS; Knight RD; Ruppert AS; Lehman A; Jarjoura D; Chen CS; Byrd JC
    J Clin Oncol; 2008 May; 26(15):2519-25. PubMed ID: 18427150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
    Wendtner CM; Hallek M; Fraser GA; Michallet AS; Hillmen P; Dürig J; Kalaycio M; Gribben JG; Stilgenbauer S; Buhler A; Kipps TJ; Purse B; Zhang J; De Bedout S; Mei J; Chanan-Khan A
    Leuk Lymphoma; 2016; 57(6):1291-9. PubMed ID: 26763349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.
    Maddocks K; Ruppert AS; Browning R; Jones J; Flynn J; Kefauver C; Gao Y; Jiang Y; Rozewski DM; Poi M; Phelps MA; Harper E; Johnson AJ; Byrd JC; Andritsos LA
    Leuk Res; 2014 Sep; 38(9):1025-9. PubMed ID: 25082342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
    Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.
    Maffei R; Fiorcari S; Bulgarelli J; Rizzotto L; Martinelli S; Rigolin GM; Debbia G; Castelli I; Bonacorsi G; Santachiara R; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
    Exp Hematol; 2014 Feb; 42(2):126-36.e1. PubMed ID: 24212063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
    Ferrajoli A; Lee BN; Schlette EJ; O'Brien SM; Gao H; Wen S; Wierda WG; Estrov Z; Faderl S; Cohen EN; Li C; Reuben JM; Keating MJ
    Blood; 2008 Jun; 111(11):5291-7. PubMed ID: 18334676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
    Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
    Mauro FR; Carella AM; Molica S; Paoloni F; Liberati AM; Zaja F; Belsito V; Cortellezzi A; Rizzi R; Tosi P; Spriano M; Ferretti A; Nanni M; Marinelli M; De Propris MS; Orlando SM; Vignetti M; Cuneo A; Guarini AR; Foà R
    Leuk Lymphoma; 2017 Jul; 58(7):1640-1647. PubMed ID: 27881039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.
    Badoux XC; Keating MJ; Wen S; Lee BN; Sivina M; Reuben J; Wierda WG; O'Brien SM; Faderl S; Kornblau SM; Burger JA; Ferrajoli A
    Blood; 2011 Sep; 118(13):3489-98. PubMed ID: 21725050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
    Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
    Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of lenalidomide in chronic lymphocytic leukemia].
    Lei W; Zhou KS; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
    Chen CI; Bergsagel PL; Paul H; Xu W; Lau A; Dave N; Kukreti V; Wei E; Leung-Hagesteijn C; Li ZH; Brandwein J; Pantoja M; Johnston J; Gibson S; Hernandez T; Spaner D; Trudel S
    J Clin Oncol; 2011 Mar; 29(9):1175-81. PubMed ID: 21189385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Itchaki G; Brown JR
    Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
    Chanan-Khan A; Miller KC; Musial L; Lawrence D; Padmanabhan S; Takeshita K; Porter CW; Goodrich DW; Bernstein ZP; Wallace P; Spaner D; Mohr A; Byrne C; Hernandez-Ilizaliturri F; Chrystal C; Starostik P; Czuczman MS
    J Clin Oncol; 2006 Dec; 24(34):5343-9. PubMed ID: 17088571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
    Liang L; Zhao M; Zhu YC; Hu X; Yang LP; Liu H
    Ann Hematol; 2016 Sep; 95(9):1473-82. PubMed ID: 27329288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.
    Schulz A; Dürr C; Zenz T; Döhner H; Stilgenbauer S; Lichter P; Seiffert M
    Blood; 2013 Mar; 121(13):2503-11. PubMed ID: 23349394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Wendtner CM; Hillmen P; Mahadevan D; Bühler A; Uharek L; Coutré S; Frankfurt O; Bloor A; Bosch F; Furman RR; Kimby E; Gribben JG; Gobbi M; Dreisbach L; Hurd DD; Sekeres MA; Ferrajoli A; Shah S; Zhang J; Moutouh-de Parseval L; Hallek M; Heerema NA; Stilgenbauer S; Chanan-Khan AA
    Leuk Lymphoma; 2012 Mar; 53(3):417-23. PubMed ID: 21879809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
    Giannopoulos K; Mertens D; Stilgenbauer S
    Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.